Skip to main content
SUIC
OTC Industrial Applications And Services

SUIC Acquires 51% of Vision Renu, Installs New CEO and Chairman in Transformative Deal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Neutral
Importance info
9
Price
$0.85
Mkt Cap
$9.687M
52W Low
$0
52W High
$2.75
52W Position
Off High info
69% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

SUIC filed a M&A and Partnerships on light trading volume (0.1× avg).

Summary

SUIC Worldwide Holdings acquires 51% of Vision Renu for 30M shares (~35% dilution), installs new CEO/Chairman, and pivots to medical devices amid a going-concern crisis.


Key Events · M&A and Partnerships · SUIC

  • Acquisition of Vision Renu

    SUIC acquired 51% of Vision Renu Corporation from its chairman in exchange for 30 million shares of SUIC common stock, representing approximately 35% of total outstanding shares on a fully-diluted basis.

  • Change of Control and Management

    Concurrent with the acquisition, Harriette Lo, Han Wei Wang, and Yee Wei Tan resigned from their director and officer roles. Chen King Te was appointed Chairman, director, and CEO; Shan Hua Peng was appointed director and CFO.

  • Vision Renu Financials

    Vision Renu reported NT$4.55M in revenue and a NT$13.63M net loss for 2025, with total assets of NT$93.6M and total equity of NT$71.6M as of December 31, 2025.

  • Strategic Pivot Amid Distress

    The acquisition comes just two months after SUIC disclosed a going-concern warning and critically low cash. The deal represents a high-risk attempt to transform the company's business into medical devices.


Analysis · SUIC · Industrial Applications And Services

SUIC Worldwide Holdings, a micro-cap company with a going-concern warning and critically low cash, has acquired a controlling stake in Vision Renu Corporation, a Taiwan-based medical device company, in exchange for 30 million shares — roughly 35% of SUIC's fully-diluted shares. The deal brings in a new management team and a business with FDA-approved products and government R&D support, but Vision Renu is loss-making (NT$13.6M loss in 2025) and has only 7 employees. The acquisition is a high-stakes pivot: it could provide a lifeline if Vision Renu's products gain traction, but the dilution is massive and the acquired entity's financials are weak. The change of control and new leadership signal a complete strategic reset for a company that was on the brink.

At the time of this filing, SUIC was trading at $0.85 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $0.00 to $2.75. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SUIC - Latest Insights

SUIC
Jul 10, 2026, 2:16 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.850
Real-time Price: $0.850 info
Change: $0 (0%) info
Market Cap: $9.687M info
SUIC
May 14, 2026, 1:26 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.8697
Real-time Price: $0.850 info
Change: -$0.0197 (-2%) info
Market Cap: $9.687M info